InfuSystem Holdings, Inc. - 10-Q Summary (Period Ended June 30, 2009)
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2009, and the six months ended on that date. InfuSystem Holdings, Inc. (formerly HAPC, Inc.) operates as a provider of ambulatory infusion pump management services, primarily for oncology patients receiving chemotherapy (specifically colorectal cancer). The company rents electronic pumps and supplies to approximately 1,550 oncology practices in the United States. It is classified as a smaller reporting company.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2009 | Six Months Ended June 30, 2009 |
|---|---|---|
| Net Revenues | $9,173,000 | $18,400,000 |
| Operating Income | $1,344,000 | $2,605,000 |
| Net Income (Loss) | $2,760,000 | $253,000 |
| Diluted EPS | $0.15 | $0.01 |
| Cash and Cash Equivalents | $5,364,000 (Balance Sheet) | $5,364,000 (Balance Sheet) |
| Net Cash Provided by Operating Activities | N/A | $3,512,000 |
| Total Debt (Current + Long-term) | $23,697,000 (Principal) | $23,697,000 (Principal) |
| Derivative Liabilities | $3,229,000 | $3,229,000 |
Note: Debt figures represent principal obligations. Interest expense for the six months ended June 30, 2009, was $1,841,000.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 4% for the quarter and 6% for the six-month period compared to the same periods in 2008, driven by new customer facilities and increased reimbursement rates.
- Profitability: The company reported a net income of $2.76 million for the quarter, a significant turnaround from a net loss of $1.80 million in the prior year quarter. This was largely influenced by a $2.006 million gain on derivatives in the current quarter versus a $1.947 million loss in the prior year.
- Cost Efficiency: Cost of revenues decreased 3% (quarter) and 8% (six months) year-over-year due to lower freight costs and reduced depreciation on older pumps. Operating margins improved as a percentage of revenue.
- Cash Position: Cash and cash equivalents decreased from $11.5 million at year-end 2008 to $5.4 million at June 30, 2009. This reduction was primarily due to $6.9 million in principal debt payments and $2.7 million in capital expenditures.
- Derivative Volatility: While the quarter showed a gain, the six-month period reflected a $636,000 loss on derivatives compared to a $3.28 million gain in the prior year six-month period, reflecting fluctuations in the fair value of warrants and interest rate swaps.
Guidance, Outlook, and Risks
Outlook: Management anticipates revenue growth from expanding the use of pumps for head, neck, and gastric cancers, in addition to colorectal cancer. The company does not believe the current financial crisis will materially impact operations or liquidity for the next 12 months.
Liquidity: Management believes current funds and operating cash flows are sufficient to fund operations for at least the next 12 months. The company has no line of credit but is exploring financing opportunities.
Risks and Contingencies:
- Debt Covenants: The company is subject to strict covenants with its primary lender, I-Flow Corporation, including fixed charge coverage and leverage ratios. It is currently in compliance but cannot pay dividends or make acquisitions without lender approval.
- Derivative Liabilities: Approximately 33.75 million warrants are classified as liabilities. Changes in their fair value directly impact net income, creating earnings volatility unrelated to core operations.
- Reimbursement Risk: Revenue recognition relies on estimates of third-party payor reimbursements (Medicare is ~31% of gross billings). Changes in healthcare policy or reimbursement rates could materially affect results.
- Earn-out Obligation: There is a potential contingent payment of up to $12 million to I-Flow in 2011 based on revenue growth targets.
Investor Verification Checklist
- Derivative Impact: Verify the extent to which net income is driven by non-cash gains/losses on warrant liabilities versus core operating performance.
- Debt Servicing: Confirm the company's ability to meet the $3.27 million in debt principal due within one year and maintain covenant compliance with I-Flow.
- Receivables Quality: Review the allowance for doubtful accounts ($1.56 million) and the $1.32 million federal income tax receivable to assess collection risks.
- Capital Expenditures: Assess the necessity and ROI of the $2.67 million in capital expenditures, primarily for new pumps and software, given the cash burn rate.
- Related Party Transactions: Review the ongoing service agreement with I-Flow and the lease arrangement with Tu-Effs (owned by the CEO) for terms and potential conflicts.